AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback